Heart Failure Management Devices - (Effective Date - 2026-06-15) 7.01.91
Effective date
Jun 15, 2026
Identified
Jun 20, 2026
Summary
Effective June 15, 2026, heart failure management devices in the outpatient setting are considered investigational, including carotid baroreflex activation therapy (e.g., Barostim device), cardiac pressure sensor devices (e.g., CardioMEMS HF system and V-Lap), cardiac contractility modulation (CCM) devices (e.g., Optimizer Smart), and combined CCM with ICD devices (CCM-D) (e.g., Optimizer Integra CCM-D System). The February 19, 2026 annual review revised the policy statement to add baroreflex activation therapy devices as investigational, added a policy statement for CCM devices, added codes 0408T-0409T, 0915T-0916T and 0923T, and added code 64654 to replace code 0266T.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.
01Already effective June 15, 2026: Billing team: the codes in the policy's code list marked (E/I) are experimental or investigational, and codes may not be covered under all circumstances.
02The listed codes include 0408T, 0409T, 0915T, 0916T, 0923T, 0933T, 0934T, 33289, 64654, 93264, C2624 and C9741, plus remote monitoring codes 0607T and 0608T.
03Code 0266T is termed as of 12/31/25 and is replaced by 64654, which is effective 01/01/26.
Codes mentioned
332896465493264C2624C9741
Original notice
Heart Failure Management Devices - (Effective Date - 2026-06-15) 7.01.91
excellusbcbs.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.